Ionis Pharmaceuticals Shares Plunge After GASK Decided Not To Initiate Phase Trial Outcome On TTRRx

By: via Benzinga
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) provided an update on its IONIS-TTRRx program. The company is evaluating IONIS-TTRRx in an ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.